

Community Consultation
Univ. of Texas - Houston

THE UNIVERSITY OF TEXAS



HOUSTON

HEALTH SCIENCE CENTER

Office of Public Affairs

To: Megan Sandell
cc: Paula Knudson, Dorey Zodrow

From: Gay E. McFarland
News Media Administrator
Office of Public Affairs
713-5003033

March 12, 1998
Megan :

Here is a wrap-up of the trauma drug study material.

A press release, "Experimental Drug Study May Help Trauma Victims," was approved by Paula Knudson and sent out March 4. As per your request, a media list is attached. An ad, which was written in my office and faxed to your office March 6, was again directed to you via e-mail on March 9 as per your request so that you could place the ad. I provided your office with the Houston Chronicle contact name and the ad rates. The press release contains my name and phone number as well as information about Health Science Center. The ad does not and should not contain any of that information. Our office only handles media requests. Public requests would go to your office to be handled by persons on your staff. We suggested the advertisement so that your office could be assured of placement. Once a press release is sent to the media, their editors make the decision to run or not run information.

The KUHF news spots are delivered at the end of each month. The spots for March were sent out Feb. 27. We did not send a news spot for March because the drug company/your office had not yet given us final copy approval.

Thank you so much.

Gay McFarland

THE UNIVERSITY OF TEXAS-HOUSTON
HEALTH SCIENCE CENTER
OFFICE OF PUBLIC AFFAIRS

Media contacts: Gay McFarland, UT-Houston Health Science Center
Phone: 713-500-3033
Relicia Johnson, Hermann Hospital
Phone: 713-790-1967

Experimental Drug Study May Help Trauma Victims

HOUSTON—(March 4, 1998)—The University of Texas-Houston Medical School and Hermann Hospital are participating in a multi trauma center research study on the drug Hu23F2G. This experimental drug, which may save the lives of seriously injured emergency room patients who are in shock and have suffered severe blood loss leaving them at high risk for organ failure and death, will be administered in Hermann's emergency room.

One of the common causes of death after trauma is damage to the heart, lungs, liver and kidneys caused by the patient's own blood cells which attack the body. Hu23F2G, developed by ICOS Corp., may prevent these blood cells from causing damage to these major organs. A possible side effect of this drug is infection, and patients in this study will receive antibiotics to minimize the risk.

Emergency room patients with these symptoms may be able to participate in this study. All patients will receive the standard treatment and care for their injuries and shock. Patients will have a two out of three chance of receiving the study drug along with standard care. Under strict guidelines set forth by the FDA (Food and Drug Administration), patients who are too severely injured and do not have family available to sign for consent may be entered into this study after diligent efforts have been made to contact family members for up to three hours following admission to the hospital. Efforts will continue to be made to contact the family, after the patient has been entered into the study.

For more information regarding this study, contact The Committee for the Protection of Human Subjects, 713-500-5828.

This news release is available on the World Wide Web at
http://www.uth.tmc.edu/uth_orgs/pub_affairs/news.html

The University of Texas-Houston Health Science Center is dedicated to building a model health sciences center for the 21st century. It is a model built on education, research and patient care devoted to the maintenance of health and the prevention of disease. Located in the world-famous Texas Medical Center, the University is the state's most comprehensive institution of health sciences, comprising schools of medicine, dentistry, public health, nursing, allied health and biomedical sciences. In 1995, the Institute of Molecular Medicine for the Prevention of Human Diseases was created.

Thursday, March 12, 1998

per your request

Subject: per your request

Date: Wed, 11 Mar 1998 14:40:38 +0000

From: GMcfarla <GMcfarla@...>

To: ...

Per your request, I am e-mailing the trauma drug ad copy. Thank you so much for your help. Best, Gay McFarland

Experimental Drug Study May Help Trauma Victims

The University of Texas-Houston Medical School and Hermann Hospital are participating in a multi trauma center research study on the drug Hu23F2G. This experimental drug, which may save the lives of seriously injured emergency room patients who are in shock and have suffered severe blood loss leaving them at high risk for organ failure and death, will be administered in Hermann's emergency room.

One of the common causes of death after trauma is damage to the heart, lungs, liver and kidneys caused by the patient's own blood cells which attack the body. Hu23F2G, developed by ICOS Corp., may prevent these blood cells from causing damage to these major organs. A possible side effect of this drug is infection, and patients in this study will receive antibiotics to minimize the risk.

Emergency room patients with these symptoms may be able to participate in this study. All patients will receive the standard treatment and care for their injuries and shock. Patients will have a two out of three chance of receiving the study drug along with standard care. Under strict guidelines set forth by the FDA (Food and Drug Administration), patients who are too severely injured and do not have family available to sign for consent may be entered into this study after diligent efforts have been made to contact family members for up to three hours following admission to the hospital. Efforts will continue to be made to contact the family, after the patient has been entered into the study.

For more information regarding this study, contact The Committee for the Protection of Human Subjects, 713-500-5828.

COMMUNITY CONSULTATION - Hemorrhagic Shock Study, PI: Dr. Fred Moore

February 3, 1998 - presentation by Chair of CPHS (Dr. Anne Dougherty) and Executive Coordinator (Paula Knudson) to Texas Medical Center Hospital Chaplain's monthly meeting.

15 TMC Chaplains present and 14 completed evaluation form extremely positive

February 19, 1998 - presentation by PI, Dr. Fred Moore and Paula Knudson to Kiwanis Club of Greater North Houston.

26 members in attendance - did not use evaluation form on this occasion but the study had their overwhelming interest and support. No negative comments.

February 19, 1998 - presentation by Paula Knudson to "Parents of Project Even Start" at Memorial Elementary School.

16 mothers present (all Hispanic) - did not use evaluation form because Spanish translation would have been necessary and we did not have it available. Generally positive response with one question as to the severity of infection. All information was conveyed through an interpreter.

March 3, 1998 - presentation by PI, Dr. Fred Moore and Paula Knudson to Hermann Hospital Volunteer Organization.

22 members of the organization present and 14 completed evaluation form. All comments were extremely positive both in writing and verbally.

March 6, 1998 - presentation by Paula Knudson to Health Fair at Our Lady of Guadalupe

7 women present only two of whom spoke any English. We had an interpreter who successfully communicated the study. However, the concept of research was very difficult to make the group understand. They do now know about the study but there was very little feedback.

March 11, 1998 - presentation by Paula Knudson to The African-American Health Coalition, Houston Metropolitan Area

18 members present and 14 completed the evaluation form. 4 people indicated that they were negative about the idea of waiving consent. Those who felt positively, however, were extremely positive.

March 17, 1998 - presentation by IRB Administrative Assistant, Cynthia Edmonds to the Asian American Coalition.

25 members present - we forgot the evaluation forms. General support for the study with one member actively dissenting.

Community Notification

The newsletter article has appeared in several newsletters (church and PTA). One negative comment was received (see note to file).

News article in Houston Chronicle, Sunday, March 22, 1998. So far no comments received.